Ost-müük Lyra Therapeutics, Inc. - LYRA CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.05 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Lyra Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 2.67 |
| Avatud* | 2.69 |
| Aastane muutus* | -50.28% |
| Päeva ulatus* | 2.65 - 2.85 |
| 52 nädala ulatus | 1.86-6.99 |
| Keskmine maht (10 päeva) | 216.46K |
| Keskmine maht (3 kuud) | 1.43M |
| Turukapitalisatsioon | 89.14M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 31.84M |
| Tulu | 1.31M |
| EPS | -1.12 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | Aug 7, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 2.77 | 0.09 | 3.36% | 2.68 | 2.98 | 2.61 |
| Jun 1, 2023 | 2.67 | 0.09 | 3.49% | 2.58 | 2.68 | 2.58 |
| May 31, 2023 | 2.55 | 0.00 | 0.00% | 2.55 | 2.56 | 2.49 |
| May 30, 2023 | 2.56 | -0.02 | -0.78% | 2.58 | 2.59 | 2.53 |
| May 26, 2023 | 2.54 | -0.06 | -2.31% | 2.60 | 2.65 | 2.33 |
| May 25, 2023 | 2.41 | -0.13 | -5.12% | 2.54 | 2.55 | 2.41 |
| May 24, 2023 | 2.55 | -0.03 | -1.16% | 2.58 | 2.59 | 2.51 |
| May 23, 2023 | 2.55 | -0.04 | -1.54% | 2.59 | 2.63 | 2.54 |
| May 22, 2023 | 2.61 | -0.03 | -1.14% | 2.64 | 2.67 | 2.56 |
| May 19, 2023 | 2.63 | 0.00 | 0.00% | 2.63 | 2.66 | 2.63 |
| May 18, 2023 | 2.70 | 0.09 | 3.45% | 2.61 | 2.71 | 2.56 |
| May 17, 2023 | 2.67 | 0.04 | 1.52% | 2.63 | 2.71 | 2.54 |
| May 16, 2023 | 2.67 | 0.12 | 4.71% | 2.55 | 2.73 | 2.54 |
| May 15, 2023 | 2.59 | 0.05 | 1.97% | 2.54 | 2.68 | 2.54 |
| May 12, 2023 | 2.65 | 0.00 | 0.00% | 2.65 | 2.69 | 2.54 |
| May 11, 2023 | 2.79 | 0.21 | 8.14% | 2.58 | 2.79 | 2.58 |
| May 10, 2023 | 2.55 | -0.09 | -3.41% | 2.64 | 2.64 | 2.54 |
| May 9, 2023 | 2.61 | 0.06 | 2.35% | 2.55 | 2.62 | 2.54 |
| May 8, 2023 | 2.59 | 0.04 | 1.57% | 2.55 | 2.68 | 2.54 |
| May 5, 2023 | 2.57 | 0.03 | 1.18% | 2.54 | 2.60 | 2.51 |
Lyra Therapeutics, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Kellaaeg (UTC) (UTC) 14:30 | Riik US
| Sündmus Lyra Therapeutics Inc at Jefferies Healthcare Conference Lyra Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Tuesday, June 13, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Lyra Therapeutics Inc Annual Shareholders Meeting Lyra Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Lyra Therapeutics Inc Annual Shareholders Meeting Lyra Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Kellaaeg (UTC) (UTC) 11:00 | Riik US
| Sündmus Q2 2023 Lyra Therapeutics Inc Earnings Release Q2 2023 Lyra Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Lyra Therapeutics Inc Earnings Release Q3 2023 Lyra Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 1.363 | 0.285 | 0 | 0 | 1.244 |
| Tulu | 1.363 | 0.285 | 0 | 1.244 | |
| Kogu tegevuskulu | 57.669 | 43.9 | 22.209 | 16.519 | 8.503 |
| Müük/Üldine/admin kulud, kokku | 17.556 | 14.206 | 9.687 | 4.487 | 3.528 |
| Uuringud ja arendus | 38.797 | 29.694 | 12.522 | 12.032 | 4.975 |
| Tulud majandustegevusest | -56.306 | -43.615 | -22.209 | -16.519 | -7.259 |
| Intressitulud (kulu), muud tulud, neto | 1.041 | 0.102 | 0.082 | 0.213 | 0.036 |
| Muud, neto | 0 | 1.194 | |||
| Netotulu enne makse | -55.265 | -43.513 | -22.127 | -16.306 | -6.029 |
| Netotulu pärast makse | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Netotulu enne erikulusid | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Netotulu | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Arvestatav tulu, v a erikulud | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Arvestatav tulu, koos erikuludega | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Jaotamisele kuuluv netotulu | -55.278 | -43.513 | -22.242 | -16.306 | -6.029 |
| Keskmine jaotamisele kuuluv aktsia kohta | 30.2357 | 12.9861 | 8.59021 | 12.3996 | 12.3996 |
| Jaotatav EPS, v a erakorralised kulud | -1.82824 | -3.35074 | -2.58923 | -1.31505 | -0.48623 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Jaotamisele kuuluv normaal-EPS | -1.79995 | -3.35074 | -2.58923 | -1.31505 | -0.48623 |
| Total Adjustments to Net Income | -0.115 | ||||
| Ootamatud kulutused (tulu) | 1.316 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0.41 | 0.011 | 0.359 | 0.993 | 0.468 |
| Kogu tegevuskulu | 17.723 | 15.166 | 15.185 | 27.318 | 12.393 |
| Müük/Üldine/admin kulud, kokku | 5.127 | 4.399 | 5.137 | 8.02 | 3.888 |
| Uuringud ja arendus | 12.596 | 9.451 | 10.048 | 19.298 | 8.505 |
| Tulud majandustegevusest | -17.313 | -15.155 | -14.826 | -26.325 | -11.925 |
| Intressitulud (kulu), muud tulud, neto | 1.072 | 0.933 | 0.06 | 0.048 | 0.014 |
| Netotulu enne makse | -16.241 | -14.222 | -14.766 | -26.277 | -11.911 |
| Netotulu pärast makse | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Netotulu enne erikulusid | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Netotulu | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Total Adjustments to Net Income | |||||
| Arvestatav tulu, v a erikulud | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Arvestatav tulu, koos erikuludega | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Jaotamisele kuuluv netotulu | -16.255 | -14.235 | -14.766 | -26.277 | -11.911 |
| Keskmine jaotamisele kuuluv aktsia kohta | 36.8327 | 36.8994 | 36.8264 | 32.4204 | 13.0088 |
| Jaotatav EPS, v a erakorralised kulud | -0.44132 | -0.38578 | -0.40096 | -0.81051 | -0.91561 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.44132 | -0.3626 | -0.40096 | -0.81051 | -0.91561 |
| Tulu | 0.41 | 0.011 | 0.359 | 0.993 | 0.468 |
| Ootamatud kulutused (tulu) | 1.316 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 100.829 | 47.918 | 75.917 | 10.119 | 24.927 |
| Raha ja lühiajalised investeeringud | 97.894 | 45.747 | 74.593 | 9.808 | 23.888 |
| Raha ja ekvivalendid | 32.55 | 45.747 | 74.593 | 9.808 | 23.888 |
| Laekumata arved, neto | 0 | 0.167 | |||
| Prepaid Expenses | 2.935 | 2.171 | 1.324 | 0.311 | 0.872 |
| Total Assets | 109.968 | 54.867 | 80.83 | 14.963 | 25.359 |
| Property/Plant/Equipment, Total - Net | 4.466 | 5.858 | 4.466 | 3.419 | 0.103 |
| Property/Plant/Equipment, Total - Gross | 8.64 | 9.737 | 7.344 | 6.248 | 2.905 |
| Accumulated Depreciation, Total | -4.174 | -3.879 | -2.878 | -2.829 | -2.802 |
| Other Long Term Assets, Total | 4.673 | 1.091 | 0.447 | 1.425 | 0.329 |
| Total Current Liabilities | 14.47 | 18.246 | 4.884 | 5.208 | 1.96 |
| Accounts Payable | 2.616 | 3.125 | 0.922 | 1.069 | 0.631 |
| Accrued Expenses | 10.579 | 5.332 | 3.962 | 4.139 | 1.329 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 29.214 | 20.551 | 6.338 | 7.635 | 2.08 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 14.744 | 2.305 | 1.454 | 2.427 | 0.12 |
| Total Equity | 80.754 | 34.316 | 74.492 | 7.328 | 23.279 |
| Redeemable Preferred Stock | 0 | 130.666 | 130.353 | ||
| Common Stock | 0.032 | 0.013 | 0.013 | 0.008 | 0.006 |
| Additional Paid-In Capital | 329.387 | 227.7 | 224.363 | 4.411 | 4.371 |
| Retained Earnings (Accumulated Deficit) | -248.675 | -193.397 | -149.884 | -127.757 | -111.451 |
| Total Liabilities & Shareholders’ Equity | 109.968 | 54.867 | 80.83 | 14.963 | 25.359 |
| Total Common Shares Outstanding | 31.8277 | 13.0072 | 12.9324 | 12.3996 | 12.3996 |
| Other Current Liabilities, Total | 1.275 | 9.789 | |||
| Lühiajalised investeeringud | 65.344 | ||||
| Other Equity, Total | 0.01 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 84.799 | 100.829 | 112.23 | 122.381 | 40.555 |
| Raha ja lühiajalised investeeringud | 82.707 | 97.894 | 109.558 | 120.669 | 33.755 |
| Raha ja ekvivalendid | 22.019 | 32.55 | 109.558 | 120.669 | 33.755 |
| Prepaid Expenses | 2.092 | 2.935 | 2.343 | 1.383 | 1.8 |
| Total Assets | 93.868 | 109.968 | 119.463 | 130.035 | 47.345 |
| Property/Plant/Equipment, Total - Net | 3.829 | 4.466 | 4.361 | 4.869 | 5.384 |
| Property/Plant/Equipment, Total - Gross | 8.64 | 9.085 | 9.314 | 9.543 | |
| Accumulated Depreciation, Total | -4.174 | -4.724 | -4.445 | -4.159 | |
| Other Long Term Assets, Total | 5.24 | 4.673 | 2.872 | 2.785 | 1.406 |
| Total Current Liabilities | 14.154 | 14.47 | 13.605 | 10.607 | 21.965 |
| Accounts Payable | 3.951 | 2.616 | 2.9 | 1.67 | 2.408 |
| Accrued Expenses | 8.693 | 10.579 | 7.975 | 6.391 | 5.334 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 27.777 | 29.214 | 26.241 | 23.786 | 24.088 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 13.623 | 14.744 | 12.636 | 13.179 | 2.123 |
| Total Equity | 66.091 | 80.754 | 93.222 | 106.249 | 23.257 |
| Common Stock | 0.032 | 0.032 | 0.032 | 0.032 | 0.013 |
| Additional Paid-In Capital | 331.001 | 329.387 | 327.63 | 325.891 | 228.552 |
| Retained Earnings (Accumulated Deficit) | -264.93 | -248.675 | -234.44 | -219.674 | -205.308 |
| Total Liabilities & Shareholders’ Equity | 93.868 | 109.968 | 119.463 | 130.035 | 47.345 |
| Total Common Shares Outstanding | 31.8368 | 31.8277 | 31.827 | 31.8264 | 13.0099 |
| Other Current Liabilities, Total | 1.51 | 1.275 | 2.73 | 2.546 | 14.223 |
| Laekumata arved, neto | 5 | ||||
| Other Current Assets, Total | 0.329 | 0.329 | |||
| Lühiajalised investeeringud | 60.688 | 65.344 | |||
| Other Equity, Total | -0.012 | 0.01 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -55.278 | -43.513 | -22.127 | -16.306 | -6.029 |
| Raha majandustegevusest | -43.385 | -25.82 | -21.143 | -13.754 | -6.64 |
| Raha majandustegevusest | 1.067 | 1.001 | 0.095 | 0.027 | 0.082 |
| Mittelikviidsed varad | 6.271 | 2.77 | 1.768 | 0.411 | -0.772 |
| Muutused tööjõus | 4.555 | 13.922 | -0.879 | 2.114 | 0.079 |
| Tulu investeeringutelt | -65.006 | -3.385 | -1.775 | -0.211 | -0.037 |
| Kapitalikulutused | -0.164 | -3.385 | -1.775 | -0.211 | -0.037 |
| Rahavood investeeringutelt | 96.257 | 0.359 | 87.703 | -0.115 | 29.213 |
| Rahavoogudesse investeerimine | -4.246 | -0.245 | -2.589 | -0.226 | -0.299 |
| Aktsiate emiteerimine (tagasiost), neto | 100.503 | 0.604 | 90.292 | 0.111 | 29.012 |
| Laenu väljastamine (kustutamine), neto | 0 | 0.5 | |||
| Rahaline kogumuutus | -12.134 | -28.846 | 64.785 | -14.08 | 22.536 |
| Muud rahavood investeeringutelt, kokku | -64.842 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.255 | -55.278 | -41.043 | -21.496 | -7.012 |
| Cash From Operating Activities | -15.85 | -43.385 | -31.221 | -20.375 | -11.905 |
| Cash From Operating Activities | 0.284 | 1.067 | 0.845 | 0.566 | 0.28 |
| Non-Cash Items | 0.884 | 6.271 | 3.69 | 1.951 | 0.844 |
| Changes in Working Capital | -0.763 | 4.555 | 5.287 | -1.396 | -6.017 |
| Cash From Investing Activities | 5.315 | -65.006 | -0.136 | -0.107 | -0.093 |
| Capital Expenditures | -0.045 | -0.164 | -0.136 | -0.107 | -0.093 |
| Cash From Financing Activities | 0.004 | 96.257 | 96.257 | 96.493 | 0.006 |
| Financing Cash Flow Items | 0 | -4.246 | -4.246 | -4.01 | -0.002 |
| Issuance (Retirement) of Stock, Net | 0.004 | 100.503 | 100.503 | 100.503 | 0.008 |
| Net Change in Cash | -10.531 | -12.134 | 64.9 | 76.011 | -11.992 |
| Other Investing Cash Flow Items, Total | 5.36 | -64.842 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | Private Equity | 28.73 | 9146730 | 0 | 2023-03-31 | MED |
| North Bridge Venture Partners | Venture Capital | 12.8248 | 4083000 | 0 | 2023-04-19 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 6.9757 | 2220830 | 0 | 2023-03-31 | LOW |
| Pura Vida Investments, LLC | Hedge Fund | 6.2725 | 1996972 | -160326 | 2023-03-31 | HIGH |
| Samsara BioCapital, LLC | Venture Capital | 5.5824 | 1777251 | 0 | 2023-03-31 | LOW |
| Polaris Venture Partners | Venture Capital | 4.4721 | 1423772 | 322920 | 2022-12-31 | LOW |
| VR Adviser, LLC | Venture Capital | 2.9028 | 924170 | 0 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4843 | 790936 | 0 | 2023-03-31 | LOW |
| Intersouth Partners | Venture Capital | 2.3187 | 738203 | 0 | 2022-12-31 | |
| Soleus Capital Management, L.P. | Hedge Fund | 1.8608 | 592417 | 0 | 2023-03-31 | HIGH |
| Medical Strategy GmbH | Investment Advisor | 1.7304 | 550918 | -41538 | 2023-01-31 | LOW |
| Ikarian Capital LLC | Hedge Fund | 1.0795 | 343685 | 0 | 2023-03-31 | HIGH |
| Ensign Peak Advisors, Inc. | Foundation | 0.9493 | 302235 | 0 | 2023-03-31 | LOW |
| Waksal (Harlan W) | Individual Investor | 0.7443 | 236966 | 0 | 2023-04-19 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4675 | 148840 | 0 | 2023-03-31 | LOW |
| Anderson (Edward T) | Individual Investor | 0.4632 | 147483 | 29000 | 2023-04-19 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.4611 | 146800 | 0 | 2023-03-31 | LOW |
| Clearline Capital LP | Hedge Fund | 0.3742 | 119128 | 0 | 2023-03-31 | HIGH |
| BofA Global Research (US) | Research Firm | 0.3291 | 104768 | 3014 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.1825 | 58092 | 58092 | 2023-03-31 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Lyra Therapeutics, Inc. Company profile
Ettevõttest Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. on kliinilises staadiumis olev terapeutiliste ravimite ettevõte. Ettevõte keskendub uudsete ravimite ja manustamislahenduste arendamisele ja turustamisele kõrva-, nina- ja kurguhaiguste (ENT) patsientide raviks. Ettevõtte tehnoloogiaplatvorm XTreo on mõeldud ravimite toimetamiseks otse kahjustatud kudedesse püsivalt ja ühekordse manustamisega. Tema tootekandidaatide hulka kuuluvad LYR-210 ja LYR-220, mis on bioresorbeeruvad polümeersed maatriksid, mida manustatakse mitteinvasiivse, kohapealse protseduuriga, et anda kuni kuus kuud kestvat ravimit kroonilise rinosinusiidi (CRS) raviks sinonasaalsetele läbipääsudele. LYR-210 on XTreo platvormil põhinev põletikuvastane implanteeritav ravimimaatriks, mis on mõeldud mometasoonfuroaadi (MF) väljutamiseks põletikulisse limaskesta kuni kuue kuu jooksul kirurgiliselt naiivsetel CRS-patsientidel. LYR-220 on uuritav ravi CRS-patsientidele, kellel on või ei ole ninapolüüpe.
| Industry: | Biotechnology & Medical Research (NEC) |
480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com